Table 3.
Cluster 1 | Cluster 2 | Cluster 3 | P | |
---|---|---|---|---|
| ||||
N | 110 | 66 | 142 | |
Gender M/F (ratio) | 58/52 | 56/10 | 104/38 | 0.00001 |
Age (average ± SD) | 55.5 ± 12 | 61.6 ± 13 | 60 ± 14 | 0.005 |
Pseudoglands | 22 (20%) | 43 (65%) | 57 (40%) | <0.00001 |
CTNNB1/APC mutations | 14 (13%) | 58 (88%) | 25 (18%) | <0.00001 |
AXIN mutations | 20 (18%) | 0 | 7 (5%) | <0.00001 |
Classic beta-catenin morphology | 15 (14%) | 33 (50%) | 28 (20%) | <0.00001 |
CTNNB1 mutations and classic beta-catenin morphology | 2 (2%) | 28 (42%) | 10 (7%) | <0.00001 |
Intratumoral inflammation | 37 (33%) | 15 (23%) | 37 (45%) | 0.23 |
Ploidy (average ± SD) | 2.9 ± 1 | 2.5 ± 0.8 | 2.4 ± 0.7 | 0.00013 |
TP53 mutations | 44 (40%) | 18 (26%) | 44 (31%) | 0.22 |
Combined CTNNB1 and TP53 mutations | 6 (5%) | 17 (26%) | 2 (1%) | |
0 with clonal progression | 8 with clonal progression | |||
HBV infection | 25 (23%) | 21 (32%) | 27 (19%) | 0.12 |